Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance

No clinical evidence on the efficacy and safety of eribulin monotherapy has been obtained by a prospective clinical study in patients with metastatic breast cancer (MBC) who had well-defined taxane resistance. The present Phase II, multicenter, single-arm, open-label study aimed to obtain the eviden...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Kenichi, Saito, Tsuyoshi, Okubo, Katsuhiko, Kimizuka, Kei, Yamada, Hirofumi, Sakurai, Takashi, Ishizuna, Kazuo, Hata, Satoshi, Kai, Toshihiro, Kurosumi, Masafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4875050/
https://www.ncbi.nlm.nih.gov/pubmed/27125669
http://dx.doi.org/10.1007/s10549-016-3808-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4875050/
https://www.ncbi.nlm.nih.gov/pubmed/27125669
http://dx.doi.org/10.1007/s10549-016-3808-x

Ejemplares similares